Related Experiment Videos
The hypertension trials
1Department of Clinical Pharmacology and Therapeutics, Imperial College of Science, Technology and Medicine, St Mary's Hospital, London, UK.
Insights
Established antihypertensive treatments like diuretics and beta-blockers reduce stroke but may not fully reverse coronary heart disease. Long-term trials are now comparing newer agents, including calcium channel blockers and ACE inhibitors, against older drugs.
Area of Science:
- Cardiology
- Pharmacology
- Internal Medicine
Background:
- Antihypertensive therapy significantly reduces stroke incidence.
- Concerns exist regarding the efficacy of established agents (diuretics, beta-blockers) in reversing coronary heart disease (CHD) in hypertensive patients.
- The potential benefits of newer antihypertensive drug classes for CHD reversal remain under investigation.
Purpose of the Study:
- To evaluate whether newer antihypertensive drug regimens offer advantages over established treatments for cardiovascular outcomes.
- To address the question of whether calcium channel blocking agents and angiotensin converting enzyme inhibitors provide superior benefits compared to older drugs in managing hypertension-related cardiovascular disease.
Main Methods:
- Conducting long-term morbidity and mortality trials.
- Comparing treatment regimens based on newer agents (calcium channel blockers, angiotensin converting enzyme inhibitors) with established agents (diuretics, beta-blockers).
Main Results:
- Previous studies confirm antihypertensive therapy's benefit in reducing stroke incidence.
- Evidence regarding the effectiveness of established agents in reversing coronary heart disease is limited.
- Ongoing trials are designed to provide data on the comparative efficacy of newer versus older antihypertensive drugs.
Conclusions:
- While established antihypertensive drugs effectively reduce stroke, their role in reversing coronary heart disease requires further clarification.
- Long-term trials investigating calcium channel blockers and angiotensin converting enzyme inhibitors are crucial for determining optimal antihypertensive strategies.
- The comparative advantages of newer antihypertensive agents over diuretics and beta-blockers in managing cardiovascular risk are under active investigation.
Abstract:
ESTABLISHED ANTIHYPERTENSIVE TREATMENT: Previous studies have clearly demonstrated the benefits of antihypertensive therapy, particularly in reducing the incidence of stroke. However, there is still concern that the full potential for reversing coronary heart disease in the hypertensive patient has not been realized by treatment with established agents, the diuretics and the beta-blockers. TRIALS ON NEWER AGENTS: A question that still remains to be answered is whether treatment regimens based on alternative drugs, including calcium channel blocking agents and angiotensin converting enzyme inhibitors, will confer an advantage over older drugs. This question is at last being addressed in long-term morbidity and mortality trials with these newer agents.